MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer
Under the terms of the agreement, Biocartis and MRCT will jointly develop selected molecular diagnostic tests for use on the fully automated Idylla(TM) platform. For each selected test, MRCT will act as a development contractor, whereas Biocartis will be responsible for the commercialization of the tests under its own label. Financial details of the partnership are not disclosed.
The first test to be developed under the partnership is a liquid biopsy test aimed at monitoring of metastatic breast cancer patients for resistance to hormone therapy. This is an important first step in the breast cancer menu that Biocartis is developing, and has a clear strategic fit within the Company's focus on liquid biopsy testing.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.